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Incidence of Inhibitor Development in a Group of Young Hemophilia A
Patients Treated Exclusively With Lyophilized Cryoprecipitate
By K Peerhnck, F R Rosendaal, and J Vermylen
The incidence of neutralizing isoantibody formation to in-
fused factor VIII in a cohort of 67 hemophilia A patients,
born between January 1, 1971 and April 30, 1990, who
had been treated exclusively with lyophilized cryoprecipi-
tate, was 6% (5.3 per 1,000 patient years of observation).
The age-dependent cumulative risk was 4.6% at 4 years of
age and 6 7% at 8 years of age. Recent reports in patients
treated with a variety of more pure concentrates show a
much higher incidence of inhibitor formation and tend to be
used äs a reference when new concentrates are intro-
duced. We believe that a patient group, such äs the one
studied here, is a more suitable reference population be-
cause these patients have been exclusively treated with a
single factor VIII preparation.
© 1993 by The American Society of Hematology.
THE DEVELOPMENT of neutralizing antibodies (m-hibitors) to mfused factor VIII (FVIII) remams a ma-
jor problem m the treatment of patients with hemophilia A
Previously untreated patients (PUPS) treated with new
monoclonal antibody (MoAb) punfied FVIII concentrates
or recombmant FVIII concentrates seem to have a higher
incidence of isoantibody formation than patients treated
with less pure products '2 Pubhshed data on cumulative
incidence of Inhibitors in patients with hemophilia A are
very divergent, ranging from 3 6% to 52% 310 The highest
mcidences are reported m the more recent pubhcations
Ehrenforth et al8 descnbe Inhibitor development m 24% (15
of 63) of all hemophilia A patients and even m 52% (14 of
27) of those with severe hemophilia, whereas Ljung et al9
find 16% (16 of 101) and 21% (16 of 77), respectively Inci-
dences are not always calculated in the same way, some
mvestigators use all known hemophilia patients äs the de-
nommator for their calculations, whereas others restnct the
denommator to all patients receivmg transfusions or to pa-
tients with severe hemophilia A The incidence rates are also
influenced by frequency of testing because a 3-month mhibi-
tor assay will detect some of the very transient mhibitors
that would be overlooked by yearly or less frequent testing.
Furthermore, most studies are not suited to evaluate the
propensity of mdividual concentrates to induce antibodies
because the majonty of patients have used a mixture of
FVIII concentrates In Belgium, patients with hemophilia A
have been treated exclusively with lyophilized cryoprecipi-
tate from local donors from 1971 till April 30, 1990, when
more pure concentrates were introduced. Most patients at-
tending the Leuven hemophilia center have been screened
yearly for inhibitor formation. They thus provide a suitable
control population for the incidence of inhibitor formation
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m patients treated with a crude FVIII preparation We ana-
lyzed a cohort of 67 patients born after January 1,1971 and
before April 30, 1990, and calculated the age-dependent cu-
mulative incidence of inhibitor development in these previ-
ously untreated patients with hemophilia A
MATERIALS AND METHODS
Patients All patients with hemophilia A born between January
l, 1971 and April 30, 1990 and attending the Leuven hemophilia
center were included in the analysis Dunng this time penod, pa-
tients have been treated exclusively with a lyophilized cryoprecipi-
tate" distnbuted by the Belgian Red Cross, which was dry-heat
treated from 1986 onwards This Cryoprecipitate was manufactured
exclusively from pooled plasma of unpaid, volunteer Belgian do-
nors Most patients attending our hemophilia center were supphed
by the Regional Blood Transfusion Center of Leuven, which col-
lected plasma through a plasmapheresis program mvolvmg a lim-
ited number (±6,000) of local donors Patients were mvited yearly
to a multidisciphnary hemophilia climc and at each visit a FVIII
inhibitor determmation was performed Additional FVIII inhibitor
assays were performed whenever the therapeutic response to trans-
fusions appeared madequate Most patients were enrolled m home
treatment programs, transfusions were admimstered either at the
flrst sign of a hemorrhage or prophylactically three times a week All
patients were Caucasian
Coagulatwn studies FVIII was measured usmg a two-stage as-
say'2 and, more recently, a one-stage assay13 adapted to an auto-
mated coagulometer ACL-810 (IL, Milan, Italy) usmg severe hemo-
philia A plasma and a micromzed sihca aPTT reagent (IL) FVIII
inhibitor levels were measured according to the Bethesda method14
from 1975 onwards Patients were classified äs inhibitor patient if
the inhibitor level exceeded l Bethesda Unit (BU)/mL on two sepa-
rate occasions Before 1975, FVIII inhibitor was measured accord-
ing to Biggs and Bidwell15
Statistical analysis The age-dependent cumulative nsk of de-
velopmg an anti-FVIII inhibitor was calculated by a Kaplan-Meier
hfe table.16 Incidences were calculated äs the ratio of the number of
mhibitors over the patient-years of follow-up Confidence intervals
(CI95) for the cumulative nsk were calculated under the assump-
tion of a binomial distnbution and for the incidence rates a Poisson
distnbution was assumed
RESULTS
Seventy-two patients with hemophilia A born between
January l, 1971 and April 4, 1990 attended our hemophilia
center. Forty-eight patients had severe hemophilia
(FVIILC, <1%), 10 had moderate hemophilia (FVIILC be-
tween 1% and 5%), and 14 had mild hemophilia (FVIIIrC
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between 5% and 40%) Five of these 72 patients (4 with mild
and l with moderate hemophilia) never received transfu-
sions and were excluded from further analysis The mean
FVIII consumption in the group with severe hemophilia
was approximately 1,500 lU/kg body weight per year
(ränge, 50 to 3,900 ILJ/kg/yr) and, on average, an Inhibitor
assay was determmed every 2 7 ± l 7 years (mean ± SD) m
this group In the group with moderate and mild hemo-
philia, the median number of exposure days to cryoprecipi-
tate was 6 (ränge, 2 to 200 days) and l patient had only a
smgle exposure Six patients seroconverted for human im-
munodeficiency virus (HIV) Two patients died durmg the
observation period, one death was acquired immunodefi-
ciency syndrome (AIDS)-related, the second was not related
to hemophilia Neither patient had an Inhibitor to FVIII
An FVIII Inhibitor developed durmg the observation pe-
nod m 4 of the 67 patients at nsk (6%) and the incidence of
Inhibitor formation was 4 per 715 patient-years of observa-
tion (56 per 1,000 patient-years of observation, CI95,
l 52% to 14 3%) In the group with severe hemophilia, the
incidence was 3 per 490 patient-years of observation (6 12
per l,000 patient-years, CI95, l 26% to 17 9%) Threeofthe
Inhibitors never exceeded 10 BU/mL despite repeated
FVIII transfusions and were classified äs low responders, the
fourth peaked at 500 BU/mL and was classified äs a high
responder (Table l) The three low responders were patients
with severe hemophilia A, the high responder was a patient
with mild hemophilia Three of the four Inhibitors devel-
oped within 5 exposure days to transfused FVIII (an expo-
sure day being a day on which at least one FVIII transfusion
was admimstered) and the age at which the inhibitor was
first detected ranged from l 7 to 7 6 years The age-depen-
dent cumulative incidence of developing an inhibitor was
4 6% (CI95, l 5% to 13 7%) at age 4 and 6 7% (CI95, 2 5% to
17 l %) at age 8 (Fig l) Restnctmg the analysis to the group
with severe hemophilia, the age-dependent cumulative inci-
dence was 4 3% (CI95, l 1% to 16 0%) at age 4 and 7 2%
(CI95, 2 3% to 20 9%) at age 8 None of the inhibitor pa-
tients had a family history of inhibitor formation or of hemo-
philia
The prevalence of Inhibitors m our total population of
hemophilia A patients was 4 7% on April 30, 1990 (l l of
234) In the subgroup of patients with severe hemophilia A,
the prevalence was 8% (10 of 126) These figures include äs
well patients with a current inhibitor äs patients with a his-
tory of inhibitor
DISCUSSION
The mtroduction of very pure FVIII concentrates (either
MoAb-punfied 01 recombmant) has raised a spinted debate
concermng the "tiue incidence of Inhibitors" in PUPS ' 2 ly
Most available data, with the exception of data on MoAb-
punfied and recombmant concentiates, have been collected
in less formally designed tnals and proportions of patients
affected ränge from 3 6% to 24%310 when all known hemo-
philia patients are considered, or from 15% to 52% of pa-
tients with severe hemophilia 5 8 9 The age-dependent cumu-
lative nsk of developing an inhibitor ranges from 20% (at 5
years of age) to 33% (at 6 years of age)4 5 810
Most mvestigators exclude patients with mild disease
from their analysis, however, m our patient group, the only
patient who developed an antibody of the high responder
type had mild disease, therefore, it seems moie appropnate
to include all patients who have been treated with FVIII in
incidence studies The nsk of inhibitor development in our
cohort of PUPS was low, ιέ, 4 of 67 patients (6%) or 5 6 per
l ,000 patient-years of observation when all patients at nsk
are considered (3 of 48 [6 25%] in the group of patients with
severe hemophilia A) The age-dependent cumulative nsk
was 6 7% at 8 years of age
Some mvestigators report similar low incidences McMil-
lan et al6 found 8 per 1,000 patient-years of observation In
the Dutch inhibitor study, 3 9 per l ,000 patient-years was
found over the period 1984 through 1989 and 4 4 per l ,000
patient-years over the period 1988 through 1990 18 How-
ever, these studies involved patients of all age groups and
thus underscore the incidence m young children who are at
the highest nsk If we restnct the analysis m our cohort to 0
to 10 years of age, an incidence of 7 5 per 1,000 patient-
years of observation (4 per 531 patient-years) is found Re-
calculating from McMillan et al6 the incidence in children
who were less than 5 years of age at entry into the study
(reahzing that these were not necessanly PUPS), we found
an incidence of 9 of 160 (5 6%) or 18 75 per 1,000 patient-
years of observation In the Dutch inhibitor study18 over the
period 1988 through 1990, thiee inhibitois were found
among 75 patients 0 to 10 years old (142 patient-years of
follow-up), which yielded an incidence of 21 per 1,000 pa-
tient-years The cumulative incidence at age 6 (äs calculated
by age-stratified hfe table analysis19) was 17 5% (2 of 15 in
the age group of l to 2 years, and l of 21 in the age group of 5
to 6 years)
The nsk of inhibitor development in PUPS is not con-
Table 1 Selected Features of Hemophilia A Patients From a Cohort Born Between January 1 1971
and April 30, 1990 Who Developed an Inhibitor
Year of Birth
1973
1975
1981
1986
Seventy of Hemophilia
Mild (8% 1 1 %)
Severe (< 1 %)
Severe (<1%)
Severe (<1%)
Age at Inhibitor
Detection (yr)
3 3
2 4
7 6
1 7
Inhibitor Titer (BU/mL)
Initial
6 5
2 4
03
5
Peak
500
24
3
5 5
April 30 1990
32
0
0
0
Exposure Days* to
FVIII Before
Inhibitor Detection
4
5
<100
4
* An exposure day is a day on which at least one FVIII transfusion was admimstered
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Fig 1. Cumulative survival without inhibitor in 67 patients with
hemophilia A. The age-dependent cumulative incidence of inhibitor
development is 4.6% at age 4 and 6.7% at age 8.
stant over age, because it steeply decreases to a very low risk
after the first few transfusions. This finding implies that the
incidence rate, calculated äs the number of events over the
patient-years of follow-up (which in fact is an average ap-
proximation of the instantaneous incidence rate), is highly
dependent on the duration of follow-up. If a group of PUPS
is followed-up from birth until age 12, the incidence rate
will be half äs high äs when they were followed-up until age
6, because virtually all inhibitors will have developed by this
age. Therefore, we are convinced that in PUP studies cumu-
lative incidence should be reported instead of incidence
rates. In the example, with all inhibitors occurring before
age 6, this cumulative incidence will be the same at age 6
and at age 12, which will render comparisons between stud-
ies more meaningful.
In non-PUPS, the incidence seems to be low, but fairly
constant over age. Therefore, in studies on these patients,
the incidence rate should be preferred, because it is indepen-
dent of the duration of follow-up, whereas the cumulative
incidence is not.
Particularly in the more recent reports, the incidence of
FVIII inhibitors is higher than in our study.5'8"10 Our data
are more in agreement with older data,3 describing patients
mainly treated with plasma or cryoprecipitate. Part of the
increase in incidence has been ascribed to an increased pro-
portion of treated patients,20 whereas the recent observation
of a higher than expected incidence of inhibitors related to
the use of one particular FVIII concentrate18·21 has shown
that differences in the production process (related to the
method of purification or viral inactivation) can lead to in-
creased immunogenicity. The low incidence described in
our report cannot be due to a low consumption of FVIII
because all described patients were enrolled in home treat-
ment and/or prophylaxis programs and patients who never
received a transfusion were excluded from analysis. We feel
that the most important difference between our patients
and those reported in other studies is that our patients have
been treated with only one FVIII preparation. It is not incon-
ceivable that switching patients from one product to an-
other entails a supplementary risk for inhibitor formation.
In addition, the risk may also increase with higher product
purity.
Because we measured inhibitors on a less than yearly
basis, our study may have overlooked very low titer, very
transient inhibitors, which are reported in the clinical stud-
ies concerning monoclonally purified and recombinant
concentrates. The clinical relevance of these transient anti-
bodies and the convenience to include them in incidence
studies are not clear at this moment.
The very low incidence and prevalence of inhibitors in
our population could also be partly influenced by the rela-
tively limited number of donors to which our patients were
exposed. Most patients attending our hemophilia center
were provided with cryoprecipitate originating from plasma
collected by the regional Blood Transfusion Center of Leu-
ven through a plasmapheresis program including only a lim-
ited number (±6,000) of local donors.
Evidence is currently accumulating that the incidence of
inhibitor formation is in part product related and is con-
nected with the complex process of purification and viral
inactivation. Each newly introduced FVIII concentrate has
to be evaluated separately on its propensity to induce neu-
tralizing antibodies in comparison with a reliable reference
population. We believe that a patient group, such äs the one
studied here, may be a suitable reference population be-
cause these patients have been exclusively treated with a
single FVIII preparation. The information provided in this
study could be used äs background for further studies to
design safe, virus-free products associated with a low inci-
dence of inhibitors.
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